A Systematic Review on the Efficacy of Amlodipine in the Treatment of Patients With Hypertension With Concomitant Diabetes Mellitus and/or Renal Dysfunction, When Compared With Other Classes of Antihypertensive Medication

American Journal of Therapeutics
Barrett W JeffersDalia Wajsbrot

Abstract

The long-term cardiovascular (CV) effects of calcium channel blockers, with special focus on amlodipine, were compared with other classes of antihypertensive medications in high-risk hypertensive patient subgroups. A systematic literature review and meta-analysis was undertaken of 38 unique randomized, active-controlled, parallel-group trials comparing amlodipine/calcium channel blockers with diuretics, β-blockers, α-blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers, with ≥6-month follow-up, and which had included assessment of blood pressure (BP) and CV events [all-cause death, CV death, myocardial infarction (MI), stroke, congestive heart failure (CHF), or major CV events (MACE: MI, CHF, stroke, and CV death)], in hypertensive patients (baseline systolic/diastolic BP ≥140/≥90 mm Hg) with either concomitant diabetes and/or renal dysfunction. In hypertensive patients with diabetes, no difference was found for amlodipine versus comparators with respect to all-cause death, CV death, MACE, and MI; a decrease in stroke risk, and an increase in CHF risk, was seen. In hypertensive patients with renal dysfunction, no difference was found for amlodipine versus comparators with respect to all-cause ...Continue Reading

References

May 1, 1992·Hypertension·M Epstein, J R Sowers
Oct 11, 2001·Journal of Hypertension·R MarinUNKNOWN Investigators of the ESPIRAL Study. Efecto del tratamiento antihipertensivo Sobre la Progresión de la Insuficiencia RenAL en
Oct 30, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·H HerlitzM Aurell
Nov 2, 2001·Diabetes Research and Clinical Practice·S Baba, UNKNOWN J-MIND Study Group
Jan 5, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Gunter WolfFuad N Ziyadeh
Dec 4, 2002·American Journal of Hypertension·Roberto FogariPierangelo Lazzari
Apr 2, 2003·Annals of Internal Medicine·Tomas BerlUNKNOWN Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Jul 9, 2003·Kidney International·Stephen L SeligerCatherine O Stehman-Breen
Apr 2, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yasuhiko IinoUNKNOWN Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators
Apr 15, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yoshiki YuiUNKNOWN Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group
Nov 2, 2004·The New England Journal of Medicine·Piero RuggenentiUNKNOWN Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators
Jul 15, 2005·Nephron. Clinical Practice·Mark S MacGregorJ Michael Boulton-Jones
May 25, 2006·Diabetes Research and Clinical Practice·Yasunori IwashimaTakeshi Yoshida
Oct 25, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Keith NorrisUNKNOWN AASK Study Group
Oct 19, 2007·Kidney International·T FujitaUNKNOWN Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators
Jan 4, 2008·Hypertension·Toshio OgiharaUNKNOWN Candesartan Antihypertensive Survival Evaluation in Japan Trial Group
Mar 21, 2008·Kidney International·G L BakrisUNKNOWN GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators
Aug 21, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tsukasa NakamuraKoichi Node
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanDavid R Matthews
Dec 5, 2008·The New England Journal of Medicine·Kenneth JamersonUNKNOWN ACCOMPLISH Trial Investigators
Feb 3, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·P KatulandaD R Matthews

❮ Previous
Next ❯

Citations

Oct 27, 2016·Clinical Pharmacology in Drug Development·Ulrike Gottwald-HostalekSteven Hildemann
Jan 7, 2017·Cardiovascular Diabetology·Alon Grossman, Ehud Grossman
Nov 4, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Kristyna KrasulovaPavel Anzenbacher
Jul 25, 2020·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Ibtsam KhairatRehab Werida

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.